Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion

20260 citationsJournal Articlegold Open Access

Authors

S.A. Piha-Paul · The University of Texas MD Anderson Cancer Center

M. De La Fuente · University of Miami

F. Iwamoto · Columbia University

J.-J. Zhu · The University of Texas Health Science Center

S. Nagpal · Palo Alto University

F. Braiteh · Comprehensive Cancer Centers of Nevada

S. Chandra

Abstract

ABM-1310 showed a favorable safety profile and encouraging intracranial activity. These findings support continued evaluation for CNS tumors and in cancer patients with prior BRAF inhibitor exposure.

Topics & Keywords

Melanoma and MAPK Pathways Brain Metastases and Treatment Fibroblast Growth Factor Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 11, Issue 2, pp. 106047-106047

DOI: 10.1016/j.esmoop.2025.106047

Field-Weighted Citation Impact: 0.00